Stay updated with breaking news from பால் ஸ்டாக்டேல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate |Oxford BioDynamics Announcements | Oxford BioDynamics: PDMR Dealing investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit ....
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 1,632,798 options over its ordinary shares of 1 pence each ( Ordinary Shares ), to certain Group employees, including 462,798 options to Chief Executive Officer, Dr Jon Burrows, 480,000 options to Chief Financial Officer, Paul Stockdale and 150,000 options to Chief Operating Officer, Thomas Guiel, who is a person discharging managerial responsibility. The options were granted under the Company s 2016 Employee Share Option Plan with an exercise price of £1 per share.
One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested optio ....
at Oxford Business Park, supporting expanded strategy Oxford, UK - 9 April 2021 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, has signed a lease agreement for new laboratory and office space at Oxford Business Park , to significantly expand its UK facilities. The 24,000 sq ft premises will house the Company s growing UK infrastructure, as it continues the execution of its expanded strategic focus , announced in December 2020. The new lease follows the recent launches of OBD s EpiSwitch The larger space will allow OBD to operate independent processing lines for commercial test development and product support, biomarker discovery contracts, clinical trial support and internal R&D projects. The new facility will also provide custom-designed space ....
About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch™, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome know ....